Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT

Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT BPL-003 is Beckley Psytech’s innovative dry powder intranasal formulation of 5-MeO-DMT using FDA approved intranasal delivery devices Data from Phase 1 will be used to select lead compound for upcoming Phase 2 in treatment resistant depression (TRD) April 05, 2022 02:00 AM Eastern…

Source